PMV Pharmaceuticals adds biotech investor to its board

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) has appointed Matt Eckler, Ph.D., to its Board of Directors, according to a company statement. Dr. Eckler is a Principal at Samsara BioCapital, where he leads the firm's public equity strategy.

Dr. Eckler has more than two decades of combined experience in healthcare investing and scientific research. Before joining Samsara BioCapital in 2025, he held investment roles at ArrowMark Partners and GMT Capital, and served as Vice President and Senior Biotech Analyst at RBC Capital Markets. Earlier in his career, he conducted research on the genetics of early brain development and circuit-level plasticity.

He holds a B.S. in biology from the University of North Carolina at Chapel Hill, a Ph.D. in molecular biology from the University of California, Santa Cruz, and completed postdoctoral work in neuroscience at UC San Diego.

The appointment comes as PMV Pharma prepares to submit a New Drug Application (NDA) for accelerated approval of its drug candidate rezatapopt for patients with platinum-resistant/refractory ovarian cancer carrying a TP53 Y220C mutation. The company plans to file the NDA in the first quarter of 2027, following the completion of enrollment in the Phase 2 monotherapy portion of its PYNNACLE pivotal clinical trial.

Rezatapopt has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of locally advanced or metastatic solid tumors with a p53 Y220C mutation, as well as Orphan Drug Designation for TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

PMV Pharma is headquartered in Princeton, New Jersey, and focuses on the discovery and development of small molecule therapies targeting p53.

You May Also Be Interested In

• Nexxen names Neil Jones interim board chair after AGM
• Dynatrace reaches FedRAMP Class D (High) initial implementation status
• NOG reports Q3 capital spending of $250M-$253M, buybacks